Albumin-based drug delivery using cysteine 34 chemical conjugates; important considerations and requirements

Mikael B. Caspersen , Matthias Kuhlmann, Karl Nicholls , Malcolm J. Saxton , Birgitte Andersen , Karen Bunting , Jason Cameron, Ken Howard

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

22 Citationer (Scopus)

Abstract

The long blood circulation time of albumin has been clinically utilized as a half-life extension technology for improved drug performance. The availability of one free thiol for site-selective chemical conjugation offers an alternative approach to current genetic fusion and association-based products. This special report highlights important factors for successful conjugation that allows the reader to design and evaluate next-generation albumin conjugates. Albumin type, available conjugation chemistries, linker length, animal models and influence of conjugation on albumin pharmacokinetics and drug activity are discussed.

OriginalsprogEngelsk
TidsskriftTherapeutic Delivery
Vol/bind8
Nummer7
Sider (fra-til)511-519
Antal sider9
ISSN2041-5990
DOI
StatusUdgivet - jul. 2017

Fingeraftryk

Dyk ned i forskningsemnerne om 'Albumin-based drug delivery using cysteine 34 chemical conjugates; important considerations and requirements'. Sammen danner de et unikt fingeraftryk.

Citationsformater